Table 1.
Characteristics of Patients and Administered T cells
| Within CD3+ (%) |
Response |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Age (years) / Gender | Histology | HPV Type | Sites of Disease | Prior Systemic Treatment | Cells (x 109) | CD4+ | CD8+ | No. of IL-2 Doses | Type | Duration or TTP (months) |
| Cervical cancer | |||||||||||
| 1 | 30/F | ASC | 18 | Iliac lymph nodes, lung, lung hilum, retroperitoneum, vaginal cuff | Cisplatin | 101.4 | 29 | 72 | 7 | PD | 1 |
| 2 | 53/F | SCC | 18 | Bone, liver, lung, lung hilum, mediastinum, pelvis | Cisplatin, carboplatin, paclitaxel, topotecan, ixabepilone, dimethane sulfonate | 126.0 | 10 | 90 | 3 | PR | 3 |
| 3 | 36/F | SCC | 16 | Iliac lymph nodes, lung hilum, mediastinum, retroperitoneum | Cisplatin, vincristine, bleomycin, gemcitabine, paclitaxel, topotecan | 152.0 | 21 | 83 | 2 | CR | 67+ |
| 4 | 55/F | SCC | 16 | Axilla, breast, liver, omentum, pleura, soft tissue | Cisplatin, carboplatin, paclitaxel, fluorouracil, irinotecan, dovitnib, pemetrexed | 80.1 | 23 | 76 | 7 | PD | 2 |
| 5 | 44/F | SCC | 18 | Brain, mediastinum, supraclavicular nodes | Cisplatin | 90.0 | 66 | 29 | 5 | PD | 2 |
| 6 | 36/F | AC | 18 | Abdominal wall, liver surface, paracolic, pelvis, retroperitoneum | Cisplatin | 74.7 | 14 | 86 | 8 | CR | 53+ |
| 7 | 59/F | AC | 18 | Abdominal wall, lung | Cisplatin, paclitaxel, carboplatin, bevacizumab | 33.4 | 36 | 58 | 8 | PD | 1 |
| 8 | 31/F | ASC | 18 | Pelvis, perihepatic mass | Cisplatin, paclitaxel | 46.1 | 64 | 29 | 9 | PD | 2 |
| 9 | 37/F | AC | 18 | Axilla, bone, lung, mediastinum, pelvis, retroperitoneum | Cisplatin, carboplatin, paclitaxel, ipilimumab | 70.2 | 33 | 59 | 6 | PD | 1 |
| 10 | 39/F | SCC | not 16/18 | Adrenal, retroperitoneum | Cisplatin, paclitaxel, bevacizumab | 100.0 | 8 | 92 | 5 | PD | 2 |
| 11 | 31/F | SCC | 16 | Cervix, iliac lymph nodes, retroperitoneum | Carboplatin, paclitaxel, bevacizumab | 77.0 | 57 | 41 | 1 | PD | 2 |
| 12 | 48/F | SCC | 16 | Bone, inguinal lymph nodes, lung, mediastinum, retroperitoneum | Cisplatin, paclitaxel, bevacizumab, listeria-based vaccine trial | 70.6 | 93 | 4 | 0 | PR | 3 |
| 13 | 30/F | SCC | 18 | Cervix, inguinal lymph nodes, lung, mediastinum | Cisplatin, brachytherapy | 101.3 | 67 | 27 | 3 | PD | 3 |
| 14 | 49/F | SCC | not 16/18 | Gastro-esophageal junction, mediastinum, retroperitoneum | Cisplatin, carboplatin, paclitaxel, topotecan, bevacizumab | 68.8 | 53 | 41 | 2 | PD | 2 |
| 15 | 61/F | AC | 16 | Bone, inguinal lymph nodes, lung | Carboplatin, docetaxel, cisplatin, topotecan, ifosfamide, adriamycin, etoposide | 73.9 | 84 | 16 | 1 | PD | 3 |
| 16 | 51/F | SCC | 18 | Liver, pelvic, peripancreatic, spleen | Cisplatin, gemcitabine, carboplatin, paclitaxel, bevacizumab | 115 | 71 | 29 | 0 | PD | 2 |
| 17 | 63/F | SCC | 18 | Lung, lung hilum | Cisplatin, carboplatin, paclitaxel, bevacizumab | 112.0 | 78 | 22 | 4 | PD | 5 |
| 18 | 35/F | NE | 18 | Lung, lung hilum, liver | Cisplatin, etoposide, topotecan, paclitaxel, bevacizumab | 9.0 | 67 | 34 | 3 | PR | 3 |
| Non-cervical cancer | |||||||||||
| 19 | 55/M | Tonsillar SCC | 16 | Axilla, lung, subcutaneous tissue | Cisplatin, fluorouracil, taxotere, carboplatin, cetuximab | 89.1 | 96 | 2 | 1 | PD | 2 |
| 20 | 60/M | Head/Neck SCC | 16 | Axilla, bone, liver, peripancreatic, periportal lymph node, pleura | Cisplatin, capecitabine, carboplatin | 150.0 | 29 | 64 | 6 | PD | 2 |
| 21 | 58/F | Anal SCC | 16 | Lung, mediastinum, pleura | Cisplatin, fluorouracil, carboplatin, paclitaxel, cetuximab, irinotecan | 31.5 | 47 | 50 | 2 | PD | 3 |
| 22 | 50/F | Anal SCC | 16 | Mediastinum, retroperitoneum | Cisplatin, fluorouracil, mitomycin C, paclitaxel, carboplatin | 69.0 | 75 | 16 | 5 | PD | 8 |
| 23 | 58/F | Anal SCC | 16 | Iliac lymph nodes, liver, retroperitoneum | Cisplatin, fluorouracil, mitomycin C | 47.5 | 86 | 9 | 1 | PD | 2 |
| 24 | 60/M | Tonsillar SCC | 16 | Lung, mediastinum | Cisplatin, docetaxel, bevacizumab, cetuximab, fluorouracil, gemcitabine | 130.9 | 41 | 51 | 3 | PR | 5 |
| 25 | 49/F | Anal SCC | 16 | Pleura | Cisplatin, fluorouracil, rigosertib, capecitabine | 133.0 | 67 | 20 | 5 | PD | 2 |
| 26 | 48/F | Anal SCC | 16 | Lung | Cisplatin, fluorouracil, mitomycin C, capecitabine | 18.4 | 47 | 50 | 5 | PR | 4 |
| 27 | 52/M | Head/Neck SCC | 16 | Axilla, chest wall, lung hilum, mediastinum, subcutaneous tissue | Cisplatin, fluorouracil, taxotere | 125.0 | 97 | 3 | 5 | PD | 2 |
| 28 | 60/M | Head/Neck SCC | 16 | Lung, lung hilum, mediastinum, para-aortic lymph node, pleura | Cisplatin, carboplatin, fluorouracil, cetuximab, pembrolizumab | 102.0 | 6 | 94 | 4 | PD | 3 |
| 29 | 56/F | Vaginal AC | 16 | Lung, lung hilum, scapula, para-spinal | Cisplatin, paclitaxel, carboplatin, pemetrexed | 107.0 | 46 | 55 | 5 | PD | 4 |
Abbreviations: AC, adenocarcinoma; ASC, adenosquamous cell carcinoma; CR, complete response; F, female; M, male; NE, neuroendocrine; PD, progressive disease; PR, partial response; SCC, squamous cell carcinoma; TTP, time to progression.